Which drugs brought in the most revenue for pharma giants in Q2 2025?
The pharmaceutical industry continues to post strong growth, with revenues in Q2 2025 once again driven by blockbuster therapies.
In this graphic, I highlight the top three selling medicines from each of the major pharma giants in Q2 2025.
Therapeutic dominance continues - oncology, immunology, and cardiometabolic diseases remain the pillars of growth.
Merck’s Keytruda and Johnson & Johnson Darzalex still lead in oncology.
No surprises in diabetes and obesity: Eli Lilly and Company’s Mounjaro and Zepbound, and Novo Nordisk’s Ozempic and Wegovy, continue their rapid ascent.
The landscape shows consistency, but also reinforces how reliant big pharma remains on a few high-performing blockbusters.
